Increasing the Use of an Anti-snoring Mouth Guard (Mandibular Advancement Appliance) to Prevent Upper Airway Collapse During Sleep in Patients With Obstructive Sleep Apnoea.
Launched by QUEEN MARY UNIVERSITY OF LONDON · Sep 16, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how to encourage patients with Obstructive Sleep Apnea (OSA) to use a special mouth guard, called a Mandibular Advancement Appliance (MAA), more regularly. OSA is a condition where the airway collapses during sleep, which can lead to poor sleep and other health issues. The researchers want to find out if providing additional support and resources can help patients use their mouth guards more effectively compared to those who receive standard care. They will also explore why some patients find it easier to wear the mouth guard than others.
To participate in the study, you need to be an adult aged 40 or older with a confirmed diagnosis of OSA. If you join the trial, you'll be randomly placed in either a group that receives extra support or one that receives regular care. Throughout the study, you'll keep a sleep diary to track how often you use the mouth guard and how well you sleep. There will also be a follow-up interview to discuss your experiences with the mouth guard. This study aims to improve treatment for OSA and help more patients get the benefits of these mouth guards.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult (≥ 40 years old)
- • Confirmed diagnosis of OSA (AHI ≥ 5)
- • Referred for MAA therapy
- • Must be able to understand, read and write English; with the assistance of a translator
- Exclusion Criteria:
- • Insufficient teeth for MAA fabrication
- • Poor dental and/or periodontal health
- • Symptomatic Temporomandibular Disorder (TMD)
- • Previously used an MAA
- • Patients with Epilepsy
About Queen Mary University Of London
Queen Mary University of London is a prestigious research-intensive institution recognized for its commitment to advancing medical science and improving health outcomes. As a leading sponsor of clinical trials, the university harnesses its academic excellence and innovative research capabilities to explore groundbreaking treatments and therapies across various medical disciplines. With a focus on collaboration, the institution engages with a diverse network of clinicians, researchers, and industry partners to ensure rigorous study design, ethical conduct, and the translation of research findings into clinical practice. Queen Mary University of London is dedicated to contributing to the global body of knowledge in healthcare through high-quality clinical research that prioritizes patient safety and welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Ama Johal
Study Chair
Queen Mary University of London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials